{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:23:03Z","timestamp":1780676583994,"version":"3.54.1"},"reference-count":43,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:p>OBJECTIVE. Extremely preterm infants mount lower antibody responses than term infants to several vaccines. The objective of this study was to measure the immunogenicity of measles-mumps-rubella and varicella vaccines in preterm and term children.<\/jats:p><jats:p>METHODS. Immune status before immunization and immune response after immunization with measles-mumps-rubella and varicella vaccines at 15 months of age were compared in 32 infants, 16 of whom were preterm (&amp;lt;29 weeks' gestation) and 16 of whom were term (\u226537 weeks' gestation) at birth. Blood was drawn before vaccination and 3 to 6 weeks thereafter. Measles antibody was measured by plaque reduction neutralization assay. Mumps and rubella immunoglobulin G were measured in available sera by enzyme-linked fluorescent immunoassay. Varicella immunoglobulin G was measured in available sera by glycoprotein enzyme-linked immunosorbent assay. Values that were above or below the assay limits were assigned values double or half those limits, respectively. The primary outcome was the geometric mean antibody titer.<\/jats:p><jats:p>RESULTS. Preterm children had lower mumps and rubella geometric mean titers than did term children before vaccine, and nearly all children were seronegative for each of the 4 vaccine antigens before immunization. Measles, mumps, rubella, and varicella geometric mean titers were similar between groups after vaccine. All children were seropositive for measles after vaccine, whereas 13 of 14 preterm and 11 of 13 term children were seropositive for mumps, 13 of 14 preterm and 13 of 13 term children were seropositive for rubella, and 11 of 16 preterm and 9 of 15 term children were seropositive for varicella.<\/jats:p><jats:p>CONCLUSIONS. Preterm children mounted antibody responses that were similar to those of term children after measles-mumps-rubella and varicella vaccines at 15 months of age.<\/jats:p>","DOI":"10.1542\/peds.2006-2241","type":"journal-article","created":{"date-parts":[[2007,3,2]],"date-time":"2007-03-02T05:39:09Z","timestamp":1172813949000},"page":"e574-e579","source":"Crossref","is-referenced-by-count":27,"title":["Measles-Mumps-Rubella and Varicella Vaccine Responses in Extremely Preterm Infants"],"prefix":"10.1542","volume":"119","author":[{"given":"Carl T.","family":"D'Angio","sequence":"first","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina A.","family":"Boohene","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Mowrer","sequence":"additional","affiliation":[{"name":"Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susette","family":"Audet","sequence":"additional","affiliation":[{"name":"Microbiology and Immunology, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn A.","family":"Menegus","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"Schmid","sequence":"additional","affiliation":[{"name":"National VZV Laboratory, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy A.","family":"Beeler","sequence":"additional","affiliation":[{"name":"Microbiology and Immunology, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"2021120901530185900_R1","unstructured":"American Academy of Pediatrics. Immunization in special clinical circumstances. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:67\u2013103"},{"key":"2021120901530185900_R2","doi-asserted-by":"crossref","unstructured":"Washburn LK, O'Shea TM, Gillis DC, Block SM, Abramson JS. Response to Haemophilus influenzae type b conjugate vaccine in chronically ill premature infants. J Pediatr.1993;123:791\u2013794","DOI":"10.1016\/S0022-3476(05)80862-5"},{"key":"2021120901530185900_R3","doi-asserted-by":"crossref","unstructured":"Greenberg DP, Vadheim CM, Partridge S, Chang SJ, Chiu CY, Ward JI. Immunogenicity of Haemophilus influenzae type b tetanus toxoid conjugate vaccine in young infants. The Kaiser-UCLA Vaccine Study Group. J Infect Dis.\u20081994;170:76\u201381","DOI":"10.1093\/infdis\/170.1.76"},{"key":"2021120901530185900_R4","doi-asserted-by":"crossref","unstructured":"Munoz A, Salvador A, Brodsky NL, Arbeter AM, Porat R. Antibody response of low birth weight infants to Haemophilus influenzae type b polyribosylribitol phosphate-outer membrane protein conjugate vaccine. Pediatrics.\u20081995;96:216\u2013219","DOI":"10.1542\/peds.96.2.216"},{"key":"2021120901530185900_R5","doi-asserted-by":"crossref","unstructured":"Heath PT, Booy R, McVernon J, et al. Hib vaccination in infants born prematurely. Arch Dis Child.\u20082003;88:206\u2013210","DOI":"10.1136\/adc.88.3.206"},{"key":"2021120901530185900_R6","doi-asserted-by":"crossref","unstructured":"Berrington JE, Cant AJ, Matthews JN, O'Keeffe M, Spickett GP, Fenton AC. Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria\/tetanus\/acellular pertussis\/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics.\u20082006;117(4). Available at: www.pediatrics.org\/cgi\/content\/full\/117\/4\/e717","DOI":"10.1542\/peds.2005-0348"},{"key":"2021120901530185900_R7","doi-asserted-by":"crossref","unstructured":"Losonsky GA, Wasserman SS, Stephens I, et al. Hepatitis B vaccination of premature infants: a reassessment of current recommendations for delayed immunization. Pediatrics.\u20081999;103(2). Available at: www.pediatrics.org\/cgi\/content\/full\/103\/2\/e14","DOI":"10.1542\/peds.103.2.e14"},{"key":"2021120901530185900_R8","doi-asserted-by":"crossref","unstructured":"Patel DM, Butler J, Feldman S, Graves GR, Rhodes PG. Immunogenicity of hepatitis B vaccine in healthy very low birth weight infants. J Pediatr.\u20081997;131:641\u2013643","DOI":"10.1016\/S0022-3476(97)70078-7"},{"key":"2021120901530185900_R9","doi-asserted-by":"crossref","unstructured":"Linder N, Handsher R, German B, et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Arch Dis Child Fetal Neonatal Ed.\u20082000;83:F24\u2013F27","DOI":"10.1136\/fn.83.1.F24"},{"key":"2021120901530185900_R10","unstructured":"Sood A, Singh D, Mehta S, Midha V, Kumar R. Response to hepatitis B vaccine in preterm babies. Indian J Gastroenterol.\u20082002;21:52\u201354"},{"key":"2021120901530185900_R11","doi-asserted-by":"crossref","unstructured":"Freitas da Motta MS, Mussi-Pinhata MM, Jorge SM, Tachibana Yoshida CF, Sandoval de Souza CB. Immunogenicity of hepatitis B vaccine in preterm and full term infants vaccinated within the first week of life. Vaccine.\u20082002;20:1557\u20131562","DOI":"10.1016\/S0264-410X(01)00493-5"},{"key":"2021120901530185900_R12","doi-asserted-by":"crossref","unstructured":"O'Shea TM, Dillard RG, Gillis DC, Abramson JS. Low rate of response to enhanced inactivated polio vaccine in preterm infants with chronic illness. Clin Res Reg Aff.\u20081993;10:49\u201357","DOI":"10.3109\/10601339309014392"},{"key":"2021120901530185900_R13","doi-asserted-by":"crossref","unstructured":"D'Angio CT, Maniscalco WM, Pichichero ME. Immunologic response of extremely premature infants to tetanus, Haemophilus influenzae, and polio immunizations. Pediatrics.\u20081995;96:18\u201322","DOI":"10.1542\/peds.96.1.18"},{"key":"2021120901530185900_R14","doi-asserted-by":"crossref","unstructured":"Khalak R, Pichichero ME, D'Angio CT. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics.\u20081998;101:597\u2013603","DOI":"10.1542\/peds.101.4.597"},{"key":"2021120901530185900_R15","doi-asserted-by":"crossref","unstructured":"Conway S, James J, Balfour A, Smithells R. Immunisation of the preterm baby. J Infect.\u20081993;27:143\u2013150","DOI":"10.1016\/0163-4453(93)94674-Z"},{"key":"2021120901530185900_R16","doi-asserted-by":"crossref","unstructured":"Kirmani KI, Lofthus G, Pichichero ME, Voloshen T, D'Angio CT. Seven-year follow-up of vaccine response in extremely premature infants. Pediatrics.\u20082002;109:498\u2013504","DOI":"10.1542\/peds.109.3.498"},{"key":"2021120901530185900_R17","doi-asserted-by":"crossref","unstructured":"Groothuis JR, Levin MJ, Lehr MV, Weston JA, Hayward AR. Immune response to split-product influenza vaccine in preterm and full-term young children. Vaccine.\u20081992;10:221\u2013225","DOI":"10.1016\/0264-410X(92)90156-E"},{"key":"2021120901530185900_R18","doi-asserted-by":"crossref","unstructured":"Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods.\u20081981;3:251\u2013260","DOI":"10.1016\/0166-0934(81)90062-8"},{"key":"2021120901530185900_R19","doi-asserted-by":"crossref","unstructured":"Wong-Chew RM, Islas-Romero R, Garcia-Garcia Mde L, et al. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine.\u20082006;24:683\u2013690","DOI":"10.1016\/j.vaccine.2005.08.045"},{"key":"2021120901530185900_R20","doi-asserted-by":"crossref","unstructured":"Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis.\u20081990;162:1036\u20131042","DOI":"10.1093\/infdis\/162.5.1036"},{"key":"2021120901530185900_R21","doi-asserted-by":"crossref","unstructured":"Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol.\u20081990;32:189\u2013193","DOI":"10.1002\/jmv.1890320310"},{"key":"2021120901530185900_R22","unstructured":"Centers for Disease Control and Prevention (CDC). Epidemiology of measles\u2014United States, 2001\u20132003. MMWR Morb Mortal Wkly Rep.\u20082004;53:713\u2013716"},{"key":"2021120901530185900_R23","unstructured":"Centers for Disease Control and Prevention (CDC). Measles\u2014United States, 2004. MMWR Morb Mortal Wkly Rep.\u20082005;54:1229\u20131231"},{"key":"2021120901530185900_R24","unstructured":"Centers for Disease Control and Prevention (CDC). Update: multistate outbreak of mumps\u2014United States, January 1\u2013May 2, 2006. MMWR Morb Mortal Wkly Rep.\u20082006;55:559\u2013563"},{"key":"2021120901530185900_R25","doi-asserted-by":"crossref","unstructured":"Meissner HC, Reef SE, Cochi S. Elimination of rubella from the United States: a milestone on the road to global elimination. Pediatrics.\u20082006;117:933\u2013935","DOI":"10.1542\/peds.2005-1760"},{"key":"2021120901530185900_R26","doi-asserted-by":"crossref","unstructured":"Yeung LF, Lurie P, Dayan G, et al. A limited measles outbreak in a highly vaccinated US boarding school. Pediatrics.\u20082005;116:1287\u20131291","DOI":"10.1542\/peds.2004-2718"},{"key":"2021120901530185900_R27","doi-asserted-by":"crossref","unstructured":"Stein CE, Birmingham M, Kurian M, Duclos P, Strebel P. The global burden of measles in the year 2000: a model that uses country-specific indicators. J Infect Dis.\u20082003;187(suppl 1):S8\u2013S14","DOI":"10.1086\/368114"},{"key":"2021120901530185900_R28","doi-asserted-by":"crossref","unstructured":"Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA.\u20082004;291:851\u2013855","DOI":"10.1001\/jama.291.7.851"},{"key":"2021120901530185900_R29","doi-asserted-by":"crossref","unstructured":"Grose C. Varicella vaccination of children in the United States: assessment after the first decade 1995\u20132005. J Clin Virol.\u20082005;33:89\u201395; discussion 96\u201388","DOI":"10.1016\/j.jcv.2005.02.003"},{"key":"2021120901530185900_R30","doi-asserted-by":"crossref","unstructured":"Miron D, Lavi I, Kitov R, Hendler A. Vaccine effectiveness and severity of varicella among previously vaccinated children during outbreaks in day-care centers with low vaccination coverage. Pediatr Infect Dis J.\u20082005;24:233\u2013236","DOI":"10.1097\/01.inf.0000154323.20387.82"},{"key":"2021120901530185900_R31","doi-asserted-by":"crossref","unstructured":"Haddad MB, Hill MB, Pavia AT, et al. Vaccine effectiveness during a varicella outbreak among schoolchildren: Utah, 2002\u20132003. Pediatrics.\u20082005;115:1488\u20131493","DOI":"10.1542\/peds.2004-1826"},{"key":"2021120901530185900_R32","unstructured":"Centers for Disease Control and Prevention (CDC). Varicella-related deaths\u2014United States, January 2003\u2013June 2004. MMWR Morb Mortal Wkly Rep.\u20082005;54:272\u2013274"},{"key":"2021120901530185900_R33","doi-asserted-by":"crossref","unstructured":"Steele RW, Hensen SA, Vincent MM, Fuccillo DA, Bellanti JA. Development of specific cellular and humoral immune responses in children immunized with live rubella virus vaccine. J Infect Dis.\u20081974;130:449\u2013453","DOI":"10.1093\/infdis\/130.5.449"},{"key":"2021120901530185900_R34","doi-asserted-by":"crossref","unstructured":"D'Angio CT, Hall CB. Timing of vaccinations in premature infants. BioDrugs.\u20082000;13:335\u2013346","DOI":"10.2165\/00063030-200013050-00004"},{"key":"2021120901530185900_R35","doi-asserted-by":"crossref","unstructured":"Asano Y, Nagai T, Miyata T, et al. Long-term protective immunity of recipients of the OKA strain of live varicella vaccine. Pediatrics.\u20081985;75:667\u2013671","DOI":"10.1542\/peds.75.4.667"},{"key":"2021120901530185900_R36","doi-asserted-by":"crossref","unstructured":"Weibel RE, Kuter BJ, Neff BJ, et al. Live Oka\/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA.\u20081985;254:2435\u20132439","DOI":"10.1001\/jama.254.17.2435"},{"key":"2021120901530185900_R37","unstructured":"Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics.\u20081986;78:748\u2013756"},{"key":"2021120901530185900_R38","doi-asserted-by":"crossref","unstructured":"Johnson CE, Shurin PA, Fattlar D, Rome LP, Kumar ML. Live attenuated varicella vaccine in healthy 12- to 24-month-old children. Pediatrics.\u20081988;81:512\u2013518","DOI":"10.1542\/peds.81.4.512"},{"key":"2021120901530185900_R39","doi-asserted-by":"crossref","unstructured":"Adenyi-Jones SC, Faden H, Ferdon MB, Kwong MS, Ogra PL. Systemic and local immune responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr.\u20081992;120:686\u2013689","DOI":"10.1016\/S0022-3476(05)80228-8"},{"key":"2021120901530185900_R40","doi-asserted-by":"crossref","unstructured":"Esposito S, Faldella G, Giammanco A, et al. Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term infants. Vaccine.\u20082002;20:2928\u20132932","DOI":"10.1016\/S0264-410X(02)00230-X"},{"key":"2021120901530185900_R41","doi-asserted-by":"crossref","unstructured":"Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis.\u20081983;147:1100","DOI":"10.1093\/infdis\/147.6.1100"},{"key":"2021120901530185900_R42","doi-asserted-by":"crossref","unstructured":"Shinefield HR, Black SB, Staehle BO, et al. Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, Varivax and Tetramune in healthy children vs. concomitant injections of M-M-R II and Tetramune followed six weeks later by Varivax. Pediatr Infect Dis J.\u20081998;17:980\u2013985","DOI":"10.1097\/00006454-199811000-00003"},{"key":"2021120901530185900_R43","doi-asserted-by":"crossref","unstructured":"Heath PT, Booy R, Griffiths H, et al. Clinical and immunological risk factors associated with Haemophilus influenzae type b conjugate vaccine failure in childhood. Clin Infect Dis.\u20082000;31:973\u2013980","DOI":"10.1086\/318132"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/3\/e574\/1112786\/zpe0030700e574.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/119\/3\/e574\/1112786\/zpe0030700e574.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T20:45:37Z","timestamp":1683751537000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/119\/3\/e574\/70413\/Measles-Mumps-Rubella-and-Varicella-Vaccine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2007,3,1]]},"published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2006-2241","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}